Tamoxifen News and Research

RSS

Tamoxifen is a drug used to treat certain types of breast cancer in women and men. It is also used to prevent breast cancer in women who have had ductal carcinoma in situ (abnormal cells in the ducts of the breast) and in women who are at a high risk of developing breast cancer. Tamoxifen is also being studied in the treatment of other types of cancer. It blocks the effects of the hormone estrogen in the breast. Tamoxifen is a type of antiestrogen. Also called tamoxifen citrate.

Hospital-based performance measures for quality of care for breast and colorectal cancer

In a move more than two years in the making, a National Quality Forum (NQF) endorsement became effective today of the first nationally recognized hospital-based performance measures for quality of care for breast and colorectal cancer.

15 Apr 2007

Although breast cancer mortality has declined as a whole, declines are greatest for women under 70

A new study shows that recent declines in breast cancer mortality rates have been most significant among women with estrogen receptor (ER)-positive tumors and women younger than 70.

4 Apr 2007

Chemotherapy and tamoxifen combination improves survival for early-stage breast cancer patients

Patients with early-stage breast cancer who are treated with both chemotherapy and tamoxifen have a higher survival rate than patients who receive only tamoxifen.

3 Apr 2007

About 50% of people fail to take medication as directed

USA Today on Thursday examined how multiple studies have shown that only about half of people with chronic conditions in the U.S. and other developed countries continue to take medication as directed.

2 Apr 2007

Lack of care for older breast cancer patients

Older women with breast cancer get a lower level of care than younger women, researchers at The University of Manchester have found.

From The University of Manchester 29 Mar 2007

Tamoxifen offers long-term benefits for breast cancer prevention among women at high risk

The trials found that the breast cancer risk reduction persists long after women stop taking tamoxifen.

20 Feb 2007

New breast cancer drug Exemestane shows great potential to save lives

In what will be welcome news to millions of women suffering from breast cancer, trials of a new drug have found it lowers oestrogen levels in women with hormone-sensitive breast cancer and has the potential to save more than 1,000 lives a year in the UK alone.

13 Feb 2007

Switching treatment to exemestane after 2-3 years on tamoxifen, improves survival

The Intergroup Exemestane Study (IES), an extensive, international study, tested the superiority of switching to exemestane (an aromatase inhibitor) from tamoxifen in patients with early breast cancer.

13 Feb 2007

Breast cancer survival rates improved by novel drug sequence

Changing the way women are treated for breast cancer could improve their overall chance of survival, according to research published in the Lancet.

13 Feb 2007

Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma

For breast cancer patients taking tamoxifen, switching to an aromatase inhibitor within three years significantly improves survival rates, according to a new study.

12 Feb 2007

Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women

Aromatase inhibitors, a type of hormone therapy used to treat advanced breast cancer in postmenopausal women, result in a small but significant increase in overall survival when compared to other hormone treatments, according to a new systematic review of studies.

30 Jan 2007

Selective marker found to indicate aggressive form of breast cancer

Researchers have linked a structural protein called nestin to a particularly deadly form of breast cancer, identifying a new biomarker that could lead to earlier detection and better treatment.

16 Jan 2007

Scientists discover how androgen plays a role in the development of prostate cancer

Scientists have discovered for the first time a specific biochemical pathway by which the sex hormone, androgen, increases levels of harmful chemicals called reactive oxygen species (ROS) in the prostate gland that play a role in the development of prostate cancer.

8 Nov 2006

Identifying breast cancer patients most likely to benefit from Aromatase Inhibitor Therapy after adjuvant radiation and Tamoxifen

While some breast cancer survivors could benefit from adding aromatase inhibitors to the standard five years of tamoxifen, a new study shows the additional therapy should be weighed carefully for each individual.

23 Oct 2006

Tamoxifen News and Research

Further Reading

Hospital-based performance measures for quality of care for breast and colorectal cancer

Although breast cancer mortality has declined as a whole, declines are greatest for women under 70

Chemotherapy and tamoxifen combination improves survival for early-stage breast cancer patients

About 50% of people fail to take medication as directed

Lack of care for older breast cancer patients

Tamoxifen offers long-term benefits for breast cancer prevention among women at high risk

New breast cancer drug Exemestane shows great potential to save lives

Switching treatment to exemestane after 2-3 years on tamoxifen, improves survival

Breast cancer survival rates improved by novel drug sequence

Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma

Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women

Selective marker found to indicate aggressive form of breast cancer

Scientists discover how androgen plays a role in the development of prostate cancer

Identifying breast cancer patients most likely to benefit from Aromatase Inhibitor Therapy after adjuvant radiation and Tamoxifen

FDA advisory panel recommends adding warning label to Tamoxifen

Aromatase inhibitors improve survival of advanced breast cancer patients compared to tamoxifen

Raloxifene reduces breast cancer risk in postmenopausal women

Basal tumours may originate from breast stem cells that have undergone genetic mishaps

Most women at high risk for breast cancer do not increase their life expectancy by taking the drug tamoxifen

Hormonal treatments reduce risk of cancer returning

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News